News
Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...
A wide variety of unapproved FDA drugs were discovered during inspections, including nearly 55,000 fake injectables and pills ...
6h
Soy Nómada on MSNMedicare and Medicaid Could Start Covering Anti-Obesity DrugsA groundbreaking initiative from the Trump administration could revolutionize access to costly weight-loss drugs under ...
Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.
Search trends reveal India’s wellness market shifting from home remedies to prescription weight-loss drugs, clinical ...
Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...
Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...
Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...
China’s drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...
Kantar’s report highlights the growing importance of personalised and functional wellness solutions, says Soumya Mohanty, MD ...
11h
Fashion Glamp on MSNA Pivotal Advance in Obesity Treatment: Eli Lilly's Oral Pill Shows Significant Weight Loss in Landmark TrialA transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results